

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Davis, Minh Tam B.
)	
David Philip LANE, et al.)	Art Unit: 1642
)	
Application Serial No. 09/403,440)	Confirmation No: 7276
)	
Filed: January 19, 2000)	Attorney's Docket No. 39749-0001 APC
)	
For: MATERIALS AND METHODS RELATING)	Customer No. 25213
TO INHIBITING THE INTERACTION OF)	
P53 AND MDM2)	

**FILED VIA EFS
ON JULY 17, 2007**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.


Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$0.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39749-0001 APC).**

Respectfully submitted,

Dated: July 17, 2007

By: 
Ginger R. Dreger (Reg. No. 33,055)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

Form PTO-1449				Attorney's Docket No. 39749-0001 APC		Application Serial No. 09/403,440	
INFORMATION DISCLOSURE STATEMENT				Applicant(s) <div style="text-align: right;">David Philip LANE, et al.</div>			
(use several sheets if necessary)				Filing Date: JANUARY 19, 2000		Group Art Unit: 1642	
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
	1.	Crook, T., et al., "p53 Point Mutation in HPV Negative Human Cervical Carcinoma Cell Lines," <i>Oncogene</i> – 6:873-875 (1991)					
	2.	Crook, T., et al., "Clonal p53 Mutation in Primary Cervical Cancer: Association With Human-Papillomavirus-Negative Tumors," <i>The Lancet</i> – 339:1070-1073 (1992)					
	3.	Jones, S.N., et al., "Rescue of Embryonic Lethality in Mdm2-Deficient Mice by Absence of p53," <i>Nature</i> – 378:206					
	4.	Leach, F.S., et al., "p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas ¹ ," <i>Cancer Research</i> – 53:2231-2234 (1993)					
	5.	de Oca Luna, R.M., et al., "Rescue of Early Embryonic Lethality in mdm2-Deficient Mice by Deletion of p53," <i>Nature</i> – 378:203 (1995)					
	6.	Oliner, J.D., et al., "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas," <i>Nature</i> – 358:80-83 (1992)					
	7.	Scheffner, M., et al., "The State of the p53 and Retinoblastoma Genes in Human Cervical Carcinoma Cell Lines," <i>Proc. Natl. Acad. Sci. USA</i> – 88:5523-5527 (1991)					

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	